Friess Associates Decreased Its Marsh & Mclennan Cos. (MMC) Stake; 5 Analysts Are Bullish ProMetic Life Sciences Inc. (TSE:PLI) Last Week

September 6, 2017 - By Vivian Park

Among 6 analysts covering ProMetic Life Sciences Inc. (TSE:PLI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. ProMetic Life Sciences Inc. had 37 analyst reports since August 10, 2015 according to SRatingsIntel. As per Tuesday, December 15, the company rating was maintained by RBC Capital Markets. On Thursday, August 25 the stock rating was maintained by RBC Capital Markets with “Outperform”. Scotia Capital maintained ProMetic Life Sciences Inc. (TSE:PLI) rating on Thursday, August 11. Scotia Capital has “Outperform” rating and $5 target. On Tuesday, November 29 the stock rating was maintained by Scotia Capital with “Outperform”. The firm has “Outperform” rating given on Tuesday, November 22 by Scotia Capital. TD Securities maintained the shares of PLI in report on Monday, April 3 with “” rating. The rating was maintained by RBC Capital Markets on Wednesday, June 15 with “Outperform”. The stock of ProMetic Life Sciences Inc. (TSE:PLI) earned “Outperform” rating by Scotia Capital on Thursday, October 27. The firm has “Outperform” rating by RBC Capital Markets given on Friday, October 21. As per Wednesday, April 19, the company rating was maintained by RBC Capital Markets. See ProMetic Life Sciences Inc. (TSE:PLI) latest ratings:

17/08/2017 Broker: National Bank Canada Rating: Sector Perform Old Target: $3.75 New Target: $2.00 Target Down
17/08/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $4.00 New Target: $3.50 Target Down
17/08/2017 Broker: TD Securities Rating: Speculative Buy Old Target: $4.50 New Target: $3.50 Target Down
07/07/2017 Broker: Scotia Capital Rating: Outperform Old Target: $4.75 New Target: $4.00 Target Down
19/06/2017 Broker: Canaccord Genuity Rating: Old Target: $4.75 New Target: $4.50 Target Down
19/04/2017 Broker: RBC Capital Markets Rating: Outperform Maintain
19/04/2017 Broker: Scotia Capital Rating: Outperform New Target: $4.75 Maintain
03/04/2017 Broker: Scotia Capital Rating: Old Target: $5.00 New Target: $4.75 Target Down
03/04/2017 Broker: TD Securities Rating: New Target: $4.50 Maintain
03/04/2017 Broker: RBC Capital Markets Rating: Outperform Old Target: $4.25 New Target: $4.00 Target Down

Friess Associates Llc decreased Marsh & Mclennan Cos. Inc. (MMC) stake by 29.53% reported in 2016Q4 SEC filing. Friess Associates Llc sold 23,460 shares as Marsh & Mclennan Cos. Inc. (MMC)’s stock rose 1.48%. The Friess Associates Llc holds 55,985 shares with $3.78 million value, down from 79,445 last quarter. Marsh & Mclennan Cos. Inc. now has $40.47B valuation. The stock increased 1.18% or $0.92 during the last trading session, reaching $78.97. About 2.84 million shares traded or 69.05% up from the average. Marsh & McLennan Companies, Inc. (NYSE:MMC) has risen 16.25% since September 6, 2016 and is uptrending. It has underperformed by 0.45% the S&P500.

Friess Associates Llc increased Nvidia Corp. (NASDAQ:NVDA) stake by 67,400 shares to 113,800 valued at $12.15 million in 2016Q4. It also upped The Trade Desk Inc. stake by 100,715 shares and now owns 213,415 shares. Nevro Corp. was raised too.

Among 11 analysts covering Marsh & McLennan (NYSE:MMC), 7 have Buy rating, 0 Sell and 4 Hold. Therefore 64% are positive. Marsh & McLennan had 22 analyst reports since September 8, 2015 according to SRatingsIntel. RBC Capital Markets maintained the stock with “Outperform” rating in Friday, February 5 report. The rating was maintained by Citigroup on Thursday, July 13 with “Buy”. The stock has “Buy” rating by Wells Fargo on Tuesday, August 8. RBC Capital Markets maintained Marsh & McLennan Companies, Inc. (NYSE:MMC) on Monday, July 10 with “Buy” rating. Credit Suisse downgraded the stock to “Neutral” rating in Monday, January 11 report. Keefe Bruyette & Woods upgraded it to “Outperform” rating and $61 target in Wednesday, January 13 report. The firm has “Outperform” rating by BMO Capital Markets given on Friday, November 4. The firm has “Hold” rating by Jefferies given on Friday, June 16. As per Thursday, July 27, the company rating was maintained by RBC Capital Markets. On Friday, April 29 the stock rating was maintained by M Partners with “Neutral”.

Since March 6, 2017, it had 0 buys, and 2 sales for $14.16 million activity. On Wednesday, March 8 the insider Glaser Daniel S sold $35.74 million. 184,305 shares were sold by Ledford Laurie, worth $13.64 million. 7,011 shares valued at $517,952 were sold by RAPPORT ROBERT J on Monday, March 13.

Investors sentiment increased to 0.97 in Q4 2016. Its up 0.08, from 0.89 in 2016Q3. It improved, as 28 investors sold MMC shares while 218 reduced holdings. 78 funds opened positions while 213 raised stakes. 423.00 million shares or 0.21% more from 422.10 million shares in 2016Q3 were reported. Amalgamated National Bank has 0.17% invested in Marsh & McLennan Companies, Inc. (NYSE:MMC). Perkins Coie Trust Company invested in 0.02% or 563 shares. Primecap Ca owns 0.74% invested in Marsh & McLennan Companies, Inc. (NYSE:MMC) for 11.08M shares. Tocqueville Asset Mgmt Ltd Partnership holds 5,691 shares. 20,003 were accumulated by Rothschild Inv Corp Il. Magellan Asset Mngmt Ltd stated it has 0% of its portfolio in Marsh & McLennan Companies, Inc. (NYSE:MMC). Nationwide Fund Advsrs accumulated 143,063 shares. 35,829 were accumulated by Jefferies Limited. Guggenheim Capital Limited Liability Company owns 809,778 shares or 0.16% of their US portfolio. Kayne Anderson Rudnick Ltd Llc reported 363,110 shares. Shell Asset Management accumulated 0.12% or 66,428 shares. 3,000 are owned by Ok. Principal Fin Gru Incorporated stated it has 756,753 shares or 0.06% of all its holdings. Wyoming-based Friess has invested 0.37% in Marsh & McLennan Companies, Inc. (NYSE:MMC). Geode Cap Lc holds 4.71M shares.

Prometic Life Sciences Inc is a Canada biopharmaceutical company. The company has market cap of $981.40 million. The Firm has two divisions: Small Molecule Therapeutics and Protein Technology. It currently has negative earnings. The Firm offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

The stock decreased 1.42% or $0.02 on September 6, reaching $1.39. About 1.47 million shares traded or 6.52% up from the average. ProMetic Life Sciences Inc. (TSE:PLI) has 0.00% since September 6, 2016 and is . It has underperformed by 16.70% the S&P500.